M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Victor A. Levin,Kathleen R. Lamborn,William M. Wara,Richard E. Davis,Michael S. B. Edwards,Jane Rabbitt,Mary Malec,Michael D. Prados +7 more
TL;DR: The combination of TPDCV chemotherapy and radiotherapy appears to be active and at least as good as published reports using radiation therapy alone, while the results for children with anaplastic astrocytoma appeared better than most reports.
Journal ArticleDOI
Using genomics to guide treatment for glioblastoma.
TL;DR: As technology continues to improve, exome and RNA sequencing will play a role in the design of clinical trials, classification of patient subgroups and identification of rare mutations that can be targeted by small-molecule inhibitors and biologic agents.
Journal Article
Autologous tumor derived gp96 evokes a tumor specific immune response in recurrent glioma patients that correlates with clinical response to therapy
Andrew T. Parsa,Courtney A. Crane,Sean P. Wilson,Nicholas Butowski,Susan M. Chang,Michael W. McDermott,Mitchel S. Berger,Anne Fedoroff,Valerie Kivett,Michael D. Prados +9 more
TL;DR: The immunomintoring results of a Phase I investigator initiated clinical trial in which recurrent high grade glioma patients were treated with autologous gp-96 demonstrated a significant increase in innate immunity when comparing final vaccination to pre-vaccination activity.
Journal ArticleDOI
Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
Cassie Kline,Payal Jain,Lindsay Kilburn,Erin R. Bonner,Nalin Gupta,John D. Crawford,Anurahda Banerjee,Roger J. Packer,Javier Villanueva-Meyer,Tracy Luks,Yalan Zhang,Madhuri Kambhampati,Jie Zhang,Sridevi Yadavilli,Bo Zhang,Krutika S. Gaonkar,Jo Lynne Rokita,Adam A. Kraya,John G. Kuhn,Winnie S. Liang,Sara A. Byron,Michael E. Berens,Annette M. Molinaro,Michael D. Prados,Adam C. Resnick,Sebastian M. Waszak,Javad Nazarian,Sabine Mueller +27 more
TL;DR: Upfront treatment-naïve biopsy provides insight into clinically relevant molecular alterations and prognostic biomarkers for H3K27-altered DIPGs.
Journal ArticleDOI
Recent advances in the treatment of central nervous system tumors
TL;DR: Temozolomide is now the new standard of care in combination with radiation therapy for newly diagnosed glioblastomas, and there remains no current role for neo-adjuvant therapy.